chartexchange

The Precision Peptide Company Locks In Exclusive Manufacturing Rights Across Its Needle-Free Line

Newsfile | Oct 22, 2026 7:00 AM EDT

HighlightsExclusive manufacturing rights secured for all four of the Company's patch formulations: BPC-157, Thymosin Alpha-1 (TA1), tirzepatide and GLP3Four patches, one U.S. manufacturer, one brand: each patch produced solely for The Precision Peptide CompanyThe Recovery Patch (BPC-157) is on sale now; 20,000 TA1 patches ordered, with delivery expected in January 2027No needle, no mixing, no measuring, no refrigeration100% manufactured and tested in the United StatesTo view an enhanced version...

Read original article